Photo of Erik Goluboff

Erik Goluboff

  • PROFESSOR Urology
Print ProfilePrint Profile

Education

  • MD, John Hopkins School of Medicine

  • Residency, Urology
    New York Presbyterian Medical Center / Columbia

  • Internship, Surgery
    John Hopkins School of Medicine

  • Fellowship, Urologic Oncology
    New York Presbyterian Medical Center / Columbia

Biography

    Dr. Erik Goluboff is an Attending Physician, Department of Urology, Mount Sinai Beth Israel Medical Center and Professor of Urology, Icahn School of Medicine at Mount Sinai. He earned an MBA at NYU's Stern School of Business, with specializations in corporate finance, financial instruments, and management. Previously, he was Director of Urology at New York-Presbyterian Hospital/The Allen Pavilion and a Professor of Clinical Urology at Columbia University College of Physicians and Surgeons. Dr. Goluboff is a board certified urologist and a Fellow Cum Laude, Phi Beta Kappa graduate of Columbia College of Columbia University and an Alpha Omega Alpha graduate of the Johns Hopkins University School of Medicine. He did a year of general surgical residency at Johns Hopkins followed by surgery and urology residency training at Columbia.  He also did a urologic oncology fellowship at Columbia, sponsored by a Ferdinand C. Valentine Fellowship from the New York Academy of Medicine and a Young Investigator Award from the American Society of Clinical Oncology. During this fellowship, he had additional training in the diagnosis and surgical treatment of urologic cancers such as prostate, bladder, kidney, penis and testis.

    Dr. Goluboff has won many awards during almost two decades in urology, including the Young Investigator Award from the National Kidney Foundation, First Prize Laboratory Investigation-Valentine Essay Contest New York Academy of Medicine, Honorable Mention- Valentine Essay Contest New York Academy of Medicine, and a Pfizer Scholar in Urology Award (twice). He has performed over 3000 surgeries including over 1000 radical prostatectomies for prostate cancer, either by the open or robotic approaches. Dr. Goluboff has authored over 150 papers and participated in many clinical trials for new drugs for urologic disorders.

    Dr. Goluboff is dedicated to the rational, efficient, and compassionate care of patients with urologic disease.

Awards

  • 2015 -
    Executive MBA Class Valedictorian
    New York University Stern School of Business

  • 2012 -
    America's Top Surgeons
    Consumers Research Council of America

  • 2011 -
    Compassionate Doctor Award

  • 2009 -
    America's Top Urologists
    Consumers Research Council of America

  • 2009 - 2011
    Patient's Choice Award

  • 2008 -
    Top Doctors New York Metro Area
    Castle Connolly

Publications

Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, Goluboff E, Nenson M, Rutman M. Exploring medical student education initiatives: Does the management of urologic conditions improve with a formal urology clinical clerkship. Journal of Medicine and the Person 2011;(9): 116-122.

Zyflamend in men with high-grade prostate intraepithelial neoplaisa. Results of PHASE 1 CLINICAL TRIAL.. JSIO 2009;.

.;.

Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007 Oct; 70(4).

.;.

Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan JM, Goluboff ET. Prostate volume and pathologic prostate cancer outcomes after radical prostatectomy. Urology 2007 Oct; 70(4).

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. Urology 2007 Mar; 69(3).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Goluboff did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central